Find Clinical Trial
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
← Back
| Study Phase |
Phase 4 |
| Therapeutic Area |
Metabolism |
| Active Substance |
GLICLAZIDE |
| Sponsor | Servier (Tianjin) Pharmaceutical Co. LTD. |
| Active Substance Code | S005702 |
| Protocol Code | IC4-5702-205-CHN |
| NCT Code | NCT00736515 |
Documents and links
| Scientific publication | READ MORE  |
Quote
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information
Report a side-effect with a drug.
All Rights Reserved. Servier does not sell its products over the Internet.
More information
Report a side-effect with a drug.
Accessibility
